ClinicalTrials.gg
Active, not recruitingNCT07449936DMEUpdated Nov 3, 2026

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

A Phase 3 interventional study of EYP-1901 and Aflibercept (2.0 mg) in Diabetic Macular Edema, DME and Diabetic Macular Edema (DME), sponsored by EyePoint Pharmaceuticals, Inc.. Active, not recruiting at 73 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by EyePoint Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 33 under way, 11 of them phase 3. Macular Edema · United States.

Planned enrollment
51st of 244
240 · median 45
Started
2026
with 9 others
Phase 3
50 of 276
5 open now
Primary completion
2027-10
later than 22 of 32 live
Registered
270th of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 51st largest by planned enrollment of the 244 interventional ones that give a count, is one of 10 that started in 2026, is one of 50 in phase 3, reaches primary completion later than 22 of the 32 other live ones, and was the 270th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

03

Conditions studied

  • Diabetic Macular Edema
  • DME
  • Diabetic Macular Edema (DME)

Browse trials for

Keywords

  • EyePoint
  • EYP-1901
  • Tyrosine Kinase Inhibitor
  • Diabetic Macular Edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously treated or treatment naïve patients with a documented diagnosis of macular edema associated with diabetic retinopathy (DR) in the study eye, with onset of disease that began at any time prior to the Screening Visit.
  • Best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 35 letters (20/200 Snellen equivalent) to 78 letters (20/32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1).
  • For previously treated participants: at least 1 injection of anti-VEGF in the past 12 months, the most recent anti-VEGF treatment for DME must not have been administered less than 12 weeks prior to the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • BCVA using ETDRS charts \<30 letters (20/250 Snellen equivalent) in the fellow eye.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    EYP-1901 2686 µg

    EYP-1901

    Drug: EYP-1901

  • Active comparator
    Aflibercept

    Drug: Aflibercept (2.0 mg)

Interventions

06

What researchers measure

Primary outcomes

  1. Average change in best corrected visual acuity (BCVA)

    BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) letter score change from Baseline to the average of Weeks 52 and 56

    Time frame: Weeks 52 and 56

Secondary outcomes

  1. Rate of injection burden

    Time frame: Week 56

07

Study locations

73 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 20 months after the start.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's planned 20 months is below that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 4, 2026
StartActual
Feb 16, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Oct 2, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07449936
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Feb 16, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorolanib

Start the discussion